ImmunoGen (IMGN) reported a loss of $0.51 per share in its fourth quarter, missing consensus forecast by 12 cents. The company�s revenue for the quarter was $7.41 million, down 41.2% on a year-over-year basis. Revenue missed consensus forecast $9.7 million.

Oncolytics Biotech (ONCYF) reported a loss of $0.02 per share in the second quarter. The company ended the quarter with $20.23 million in cash and cash equivalents on its balance sheet.

BioCryst Pharmaceuticals (BCRX) reported a loss of $0.22 per share in its second quarter, beating consensus forecast by 4 cents. The company reported revenue of $4.79 million, down 81.5% on a year-over-year basis. Revenue beat consensus forecast by $0.87 million.

Navidea Biopharm (NAVB) reported a loss of $0.04 per share in its second quarter, missing consensus forecast by a penny. The company reported revenue of $5.39 million, up 87.8% on a year-over-year basis. Revenue beat consensus forecast by $0.15 million.

Teva Pharmaceutical Industries (TEVA) reported second-quarter earnings of $1.25 per share, beating consensus forecast by 5 cents. The company reported revenue of $5.04 billion, up 1.4% on a year-over-year basis. Revenue beat consensus forecast by $170 million.

Intercept Pharma (ICPT) reported a loss of $3.14 per share in the second quarter, beating consensus forecast by 56 cents. The company reported revenue of $5.52 million, beating consensus forecast $4.06 million.